HOUSTON, April 15, 2020 /PRNewswire/ -- Moleculin
Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a
clinical stage pharmaceutical company with a broad portfolio of
drug candidates, today announced that Dr. Dominique Schols of the Rega Institute has
joined the Moleculin development team as a consultant.
The announcement follows on the heels of the discovery by
researchers at the University of Frankfurt
(https://www.researchsquare.com/article/rs-17218/v1) that 2
deoxy-D-glucose (2-DG, and the active compound in WP1122) inhibited
SARS-CoV–2 replication in susceptible cell lines.
The Rega Institute of Medical Research, Belgium, is one of the premier medical
research institutes in Europe and
was responsible for breakthrough discoveries that led the fight
against HIV, among others. Dr. Dominique
Schols is Professor and Head of the Laboratory of Virology
and Chemotherapy, Department of Microbiology and Immunology and
Transplantation of the University of Leuven, Belgium.
"We are so fortunate to have someone of the caliber of Dr.
Schols join our team," commented Walter
Klemp, Chairman and CEO of Moleculin. "We believe
Dominique's depth of understanding and contacts throughout the
virology community will prove invaluable in accelerating the
development of WP1122 as a treatment for COVID-19 and other viral
diseases."
Dr. Dominique Schols added:
"WP1122 represents a novel approach of targeting the virus-induced
host metabolism that is essential for the virus's
propagation. It also could be complementary to other current
antiviral strategies. I am very excited to be working on this
potentially game-changing technology."
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc.
is a clinical stage pharmaceutical company focused on the
development of a broad portfolio of oncology drug candidates for
the treatment of highly resistant tumors and viruses. The Company's
clinical stage drugs are: Annamycin, a Next Generation
Anthracycline designed to avoid multidrug resistance mechanisms
with little to no cardiotoxicity, being studied for the treatment
of relapsed or refractory acute myeloid leukemia, more commonly
referred to as AML; WP1066, an Immune/Transcription Modulator
capable of inhibiting p-STAT3 and other oncogenic transcription
factors while also stimulating a natural immune response, under
investigation for brain tumors, pancreatic cancer and hematologic
malignancies; and WP1220, an analog to WP1066, being developed for
the topical treatment of cutaneous T-cell lymphoma. Moleculin is
also engaged in preclinical development of additional drug
candidates, including additional immune/transcription modulators,
as well as WP1122, a compound capable of metabolism/glycosylation
Inhibition.
For more information about the Company, please
visit http://www.moleculin.com.
Forward-Looking Statements
Some of the statements in
this release are forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995, which involve risks and
uncertainties. Forward-looking statements in this press release
include, without limitation, the ability of WP1122 to demonstrate
safety and efficacy in humans. Although Moleculin believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. Moleculin Biotech has attempted to
identify forward-looking statements by terminology including
''believes,'' ''estimates,'' ''anticipates,'' ''expects,''
''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,''
''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. These statements are
only predictions and involve known and unknown risks,
uncertainties, and other factors, including those discussed under
Item 1A. "Risk Factors" in our most recently filed Form 10-K filed
with the Securities and Exchange Commission ("SEC") and updated
from time to time in our Form 10-Q filings and in our other public
filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. We undertake
no obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events. The
Company cautions investors not to place undue reliance on the
interim results announced today.
Contacts
James
Salierno / Carol Ruth
The Ruth Group
646-536-7028 / 7000
jsalierno@theruthgroup.com
cruth@theruthgroup.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/moleculin-announces-leading-virologist-joins-development-team-301040789.html
SOURCE Moleculin Biotech, Inc.